Core Insights - The growth of short-dated options is identified as a key industry trend, with MIAX highlighting the success of new Monday and Wednesday expirations in single stocks, which are expected to contribute to volume growth in 2026 [1][6] Financial Performance - MIAX reported total net revenue of $431 million for the full year 2025, a 56% increase from the prior year, with adjusted EBITDA more than doubling to $199 million and an adjusted EBITDA margin improving to 46%, reflecting a 1,600 basis point year-over-year increase [4] - For Q4 2025, total net revenue reached $125 million, up 52% year over year, with adjusted EBITDA also more than doubling to $62 million and an adjusted EBITDA margin expanding 1,400 basis points to 50% [5] Market Share and Volume - MIAX achieved a record market share of 18.2% in multi-listed options during Q4, up from 15.9% in the prior-year period, with average daily volume at 11.1 million contracts, representing a 46% year-over-year increase, outpacing the industry average growth of approximately 28.4% [2][6] Strategic Developments - MIAX completed a secondary offering of 7.8 million shares in December 2025, enhancing liquidity without receiving proceeds [9] - The company sold 90% of MIAX Derivatives Exchange (MIAXdx) to Robinhood Markets while retaining a 10% equity stake, allowing MIAX to focus on core offerings [10] - MIAX launched its trading floor in Q3 2025, performing in line with expectations and demonstrating the value of floor-based trading in a hybrid market structure [10] Future Initiatives - MIAX plans to launch Bloomberg Indices futures products in Q2 2026, having rescheduled the launch to ensure reliability and performance [12] - The company will introduce retail-sized contracts aimed at retail broker demand for low trading fees, with a focus on execution costs [13] - MIAX expects adjusted operating expenses for 2026 to be between $265 million and $275 million, reflecting a 13% to 18% increase over 2025 due to headcount and technology costs for new product launches [17] Segment Performance - In Q4, options generated net revenue of $107 million, up 46% year over year, while equities revenue increased to $6 million from $2 million, and futures revenue decreased to $5 million from $6 million [16]

Core Viewpoint - Mosaic is facing challenges in passing through higher sulfur costs due to affordability constraints, particularly in the U.S. market, while international markets are experiencing stronger demand dynamics [1][2]. Market Dynamics - U.S. DAP pricing remains stable due to affordability issues, while international DAP prices have increased, with netbacks at a premium to NOLA pricing [2]. - Despite lower overall North American potash and phosphate shipments in 2025, Mosaic's sales volumes in North America showed resilience, indicating market share gains [3]. - U.S. phosphate demand sharply declined in Q4 2025, but there are signs of increased inquiries as farmers prepare for spring planting [4][5]. Operational Performance - Mosaic produced 1.7 million tons of phosphate in Q4 2025, with expectations to produce at least 7 million tons in 2026 [7]. - The company highlighted improvements in phosphate recovery and production, with Florida rock production reaching its highest level in three years [6]. - Potash production is expected to reach around 9 million tons in 2026, maintaining levels similar to 2025 [9]. Cost Management - Sulfur prices spiked at the end of 2025, expected to significantly compress margins in phosphate and Mosaic Fertilizantes into H1 2026 [10]. - The company achieved $150 million in cost savings ahead of schedule in 2025 and is targeting an additional $100 million in 2026 [11]. Cash Flow and Capital Allocation - 2025 was challenging for cash flow due to inventory builds, with working capital reducing cash flow by $960 million [12]. - For 2026, Mosaic expects a significant working capital release of $300 million to $500 million driven by demand recovery and improved production [14]. - Capital expenditures for 2026 are projected at about $1.5 billion, primarily for expansions and waste-related projects [15]. Growth Initiatives - Mosaic's Biosciences platform is identified as a growth driver, with net sales doubling to $68 million in 2025 and expectations for further doubling in 2026 [18]. - The company is pursuing strategic alternatives for selected Brazilian assets and potential monetization of Florida land holdings [20].

Core Insights - MP Materials executives highlighted 2025 as a "landmark year," with increased rare earth oxide output, progress in magnet production, and new long-term customer agreements amid rising demand for NdPr [2] Production and Sales Performance - The company reported a doubling of separated NdPr oxide output to 2,599 metric tons in 2025, with an annualized run rate nearing 4,000 metric tons by year-end, supported by record production in December [3] - Total oxide sales volumes increased by 75% to nearly 2,000 metric tons for the year, with over 50,000 metric tons of rare earth oxide produced, marking a record annual performance and maintaining Mountain Pass as the world's second-largest REO producer [4] Financial Performance - CFO noted that upstream production exceeded 50,000 metric tons of REO and concentrate, up 12% from 2024, and indicated that after mid-2025, the company will stop reporting upstream sales volumes and realized pricing [5] - The company's price protection agreement (PPA) contributed $51 million in the fourth quarter, effectively realizing a $110 per unit purchase price floor for sold products, alongside contributions from stockpiled inventory [6] - Higher realized prices, PPA benefits, and cost reductions led to a return to profitability in the materials segment, generating $40.3 million of adjusted segment EBITDA in the quarter [7]

Core Insights - Montrose Environmental Group reported a record year in 2025 with revenue of $830.5 million and consolidated adjusted EBITDA of $116.2 million, marking a 19.3% revenue increase compared to 2024, driven by 12.7% organic growth, exceeding the long-term target of 7% to 9% [3][4][7] Financial Performance - Fourth-quarter revenue rose to $193.3 million from $189.1 million a year earlier, with consolidated adjusted EBITDA at $23.9 million, or 12.4% of revenue, down from 14.4% in the prior-year quarter due to lower margins in specific segments and expenses related to the renewables business [1] - Consolidated adjusted EBITDA increased 21.3% year over year, with the adjusted EBITDA margin expanding to 14% in 2025, representing an improvement of 180 basis points since 2022 [2] Segment Performance - The Assessment, Permitting and Response (APR) segment saw revenue increase by 43% to $307.4 million, with adjusted EBITDA rising to $68.5 million, maintaining a margin of 22.3% [10][11] - The Measurement and Analysis segment's revenue grew 9.6% to $245.9 million, with adjusted EBITDA improving to 26.2% of revenue, a 370 basis point margin expansion [20] - The Remediation and Reuse segment's revenue increased by 7.8% to $277.3 million, although adjusted EBITDA declined to $36.3 million due to losses associated with the renewables wind-down [20] Cash Flow and Balance Sheet - Montrose generated $107 million in operating cash flow, representing a 93% conversion of consolidated adjusted EBITDA, significantly above the long-term target of 50% [6][8] - The company fully redeemed $122 million of preferred stock early, simplifying its capital structure and ending 2025 with a leverage ratio of 2.5x and $225 million in liquidity [9] Growth Opportunities - Management emphasized growth areas such as PFAS, which currently accounts for 10-15% of revenue with expected double-digit growth, and a water treatment total addressable market exceeding $250 billion [5][15] - The company plans to continue investing 1% to 2% of revenue annually in technology and growth capital expenditures while initiating a $40 million share repurchase program [19] 2026 Guidance - Montrose provided 2026 guidance of $840 million to $900 million in revenue and $125 million to $130 million in consolidated adjusted EBITDA, implying approximately 10% adjusted EBITDA growth versus 2025 [16][17] - The company expects revenue to be split evenly between the first and second halves of 2026, with adjusted EBITDA anticipated to be 40% in the first half and 60% in the second half [17][18]

Core Insights - The Marcus Corporation reported solid fourth-quarter results for fiscal 2025, with both Theatres and Hotels & Resorts divisions showing year-over-year revenue and earnings growth, outperforming their respective industries [4] Theatres Division - Fourth-quarter revenue reached $123.8 million, a 2.2% increase year over year, aided by a fiscal calendar shift that contributed significantly to admissions and attendance revenue growth [1] - Comparable theatre admission revenue increased by 6.1% year over year, attributed to a favorable mix of family films, while average admission price rose by 12.7% [5] - Theatres Adjusted EBITDA was $24.1 million, up just under 2% year over year [7] Hotels & Resorts Division - The Hotels & Resorts division achieved fourth-quarter revenues of $60.4 million, a 5% increase year over year, with RevPAR rising by 3.5% [8][9] - The division outperformed industry benchmarks, with a RevPAR increase of 2.7 percentage points compared to comparable upper upscale hotels nationally [10] - Hotels Adjusted EBITDA was $7.3 million, up 3.4% year over year, driven by higher revenue [11] Financial Performance - For the full year of fiscal 2025, consolidated revenue increased by just over 3%, while operating income was reported at $17.1 million [2] - Consolidated Adjusted EBITDA for the fourth quarter was $26.8 million, reflecting a 3.6% year-over-year increase [3] - The company reported fourth-quarter operating cash flow of $48.8 million, down from $52.6 million a year earlier [14] Capital Allocation - Capital expenditures for the fourth quarter totaled $22.4 million, with expectations for a significant reduction in capital expenditures in fiscal 2026 [15][16] - The company repurchased approximately 118,000 shares for $1.8 million in the quarter, with total repurchases for fiscal 2025 exceeding 1.1 million shares [15][18] Strategic Initiatives - The company is focusing on enhancing customer experience through technology and loyalty programs, including a redesigned digital ticketing experience and various customer retention initiatives [19][20] - Management expressed optimism about the 2026 film slate, anticipating a stronger mix of tent-pole films and family content [21]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by April 7, 2026, to serve as lead plaintiff [2] - The lead plaintiff acts on behalf of other class members in directing the litigation [2] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for securities class action settlements since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3] Group 3: Case Allegations - The lawsuit alleges that Inovio made false and misleading statements regarding the manufacturing of its CELLECTRA device and the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024 [4] - It is claimed that Inovio lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [4] - The lawsuit asserts that when the true details became known, investors suffered damages due to the misleading public statements made by the defendants [4]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates with a team of experienced and qualified news journalists across key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans to maintain quality and best practices in content production [5]

Group 1 - Geopolitical risks are now driving a rise in mining stocks, marking a shift from traditional views of the sector as a bet on industrial growth to strategic investments linked with security and supply control [1][2] - Over the past six months, the US mining sector (XME) has gained 48%, while the international sector (PICK) has rallied by 57%, compared to an 8% return in the S&P 500 [2] - Historically, mining stocks were vulnerable during periods of geopolitical volatility, as trade wars and military conflicts typically led to weaker growth expectations and lower demand for raw materials [3] Group 2 - The relationship between mining stocks and global growth has changed, with recent geopolitical events disrupting global metals flows and raising risks around energy and shipping [4] - New supply constraints are driven by tighter environmental policies in Western countries and resource nationalism in regions like Latin America and Africa, particularly in the Democratic Republic of Congo [5] - Geopolitical risks now signal tighter supply and increased scarcity premiums, which effectively reduce miners' cost of capital [6] Group 3 - The AI boom is benefiting mining stocks as investors shift from soft assets to those tied to energy, materials, and physical production [7] - Data center expansion has led to increased demand for metals, further supporting the mining sector [8]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased ordinary shares of uniQure N.V. between September 24, 2025, and October 31, 2025, about the upcoming lead plaintiff deadline on April 13, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought uniQure shares during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3]. - To serve as lead plaintiff, individuals must file a motion with the Court by April 13, 2026 [3]. Group 2: Case Background - The lawsuit alleges that uniQure misrepresented and/or failed to disclose critical information regarding the design of its Pivotal Study for a drug candidate targeting Huntington's Disease, including the lack of full FDA approval [5]. - It is claimed that uniQure downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline due to the necessity of additional studies [5]. - As a result of these misrepresentations, the lawsuit asserts that the statements made by uniQure regarding its business and prospects lacked a reasonable basis, leading to investor damages when the truth was revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in this area [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in terms of settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4].

Innovations often (but not always) drive life-changing returns for the companies that engineer them and the people who get in on the ground floor. That's why investors should sometimes look toward smaller, innovative companies, as some have highly attractive upside potential.One such corporation to consider is TransMedics Group (TMDX +7.78%), which is helping revolutionize the organ transplant market. For those with $5,000 to spare (outside of your emergency fund), here's why investing that money in TransMe ...